Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (701-710 of 1,095) with videos related to

Pageof 110
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Pathogens (Basel, Switzerland)|March 26, 2025
Improving HCV Screening in Addiction Care Centers with Plasma Separation CardsFernando Velásquez Orozco, David Tabernero, María Gabriela Barbaglia, et al.
Critical Reviews in Oncology/Hematology|February 9, 2025
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative reviewFederica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Immunotherapy|August 6, 2024
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 studyShobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 12, 2006
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patientsFrederik Nevens, Jane N Zuckerman, Andrew K Burroughs, et al.
Plos One|June 6, 2012
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeFrancisco Rodriguez-Frías, David Tabernero, Josep Quer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infectionPatrick Marcellin, David K Wong, William Sievert, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Journal of Kidney Cancer and VHL|October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI StudyGiulia Airò, Annalisa Guida, Alessio Gili, et al.
Pageof 110

Showing results (701-710 of 1,095) with videos related to

Sort By:
Pageof 110
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Pathogens (Basel, Switzerland)|March 26, 2025
Improving HCV Screening in Addiction Care Centers with Plasma Separation CardsFernando Velásquez Orozco, David Tabernero, María Gabriela Barbaglia, et al.
Critical Reviews in Oncology/Hematology|February 9, 2025
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative reviewFederica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Immunotherapy|August 6, 2024
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 studyShobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 12, 2006
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patientsFrederik Nevens, Jane N Zuckerman, Andrew K Burroughs, et al.
Plos One|June 6, 2012
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeFrancisco Rodriguez-Frías, David Tabernero, Josep Quer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infectionPatrick Marcellin, David K Wong, William Sievert, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Journal of Kidney Cancer and VHL|October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI StudyGiulia Airò, Annalisa Guida, Alessio Gili, et al.
Pageof 110